Announcements Trials
Browse Landscape

Phase

Phase 3 9Phase 4 3Phase 2 3Phase 2/3 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Letrozole 23Docetaxel 17Cyclophosphamide 13Zoledronic Acid 12Trastuzumab 12Anastrozole 12exemestane 11Tamoxifen 11Paclitaxel 11Capecitabine 10Fulvestrant 8Epirubicin 8pegfilgrastim 7Saline Solution 7Bupivacaine 7pertuzumab 6liposomal doxorubicin 6abemaciclib 6Sodium Chloride 6Filgrastim 6Carboplatin 6pegylated granulocyte colony-stimulating factor 5palbociclib 5Ropivacaine 5Dexmedetomidine 5Bevacizumab 5ribociclib 4eribulin 4Vinorelbine 4Tranexamic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Toremifene × Breast × Clear all
NCT02344940 2019-09-24

TTOS

Shanghai Jiao Tong University School of Medicine

Phase 4 Completed
104 enrolled
Breast

Breast Neoplasms

NCT03238703 2018-12-27

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Fred Hutchinson Cancer Center

Phase 4 Withdrawn
Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT02089854 2016-12-02

AETNBC

Peking Union Medical College Hospital

Phase 4 Unknown
800 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡